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Although homocysteine (Hcy) has been widely implicated in the etiology of various physical
health impairments, especially cardiovascular diseases, overwhelming evidence indicates
that Hcy is also involved in the pathophysiology of schizophrenia and affective disorders.
There are several mechanisms linking Hcy to biological underpinnings of psychiatric
disorders. It has been found that Hcy interacts with NMDA receptors, initiates oxidative
stress, induces apoptosis, triggers mitochondrial dysfunction and leads to vascular
damage. Elevated Hcy levels might also contribute to cognitive impairment that is widely
observed among patients with affective disorders and schizophrenia. Supplementation
of vitamins B and folic acid has been proved to be effective in lowering Hcy levels.
There are also studies showing that this supplementation strategy might be beneficial
for schizophrenia patients with respect to alleviating negative symptoms. However, there
are no studies addressing the influence of add-on therapies with folate and vitamins B on
cognitive performance of patients with schizophrenia and affective disorders. In this article,
we provide an overview of Hcy metabolism in psychiatric disorders focusing on cognitive
correlates and indicating future directions and perspectives.
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INTRODUCTION
Homocysteine (Hcy) is one of the non-protein amino acids
that is produced in one-carbon metabolism. Two enzymatic
pathways are involved in Hcy metabolism—re-mehtylation to
methionine and trans-sulfuration to cysteine and taurine. The
efficiency of Hcy catabolism depends on the availability of
folate, vitamin B12 and vitamin B6. Tans-sulfuration to cysteine,
which forms glutathione, is catalyzed by cystathionine beta
synthase (CBS) and cystathionase. In turn, conversion from
Hcy to methionine is a multistep reaction with a number
of enzymes being involved including Hcy methyltransferase,
methionine synthase (MS) and methionine synthase reductase
(MTRR), as well as the methylenetetrahydrofolate reductase
(MTHFR; Scott and Weir, 1998). There are two common poly-
morphisms located in the MTHFR gene—C677T and A1298C
that may lower the activity of MTHFR and lead to increased
Hcy levels. The most common one—C677T polymorphism,
which is present in 10–12% of population (Gilbody et al.,
2007), contributes to the expression of a thermolabile vari-
ant of MTHFR. Other factors might also increase Hcy level
including higher age, male gender, cigarette smoking, alcohol
abuse or dependence, low dietary intake of folate and vita-
mins B, renal dysfunction and certain medications (e.g., sodium
valproate and lamotrigine, diuretics, fibrates) (Frankenburg,
2007). In addition, there is an inverse relationship between
Hcy and both folate and vitamin B12 levels (Yoshino et al.,
2010).
Several lines of evidence indicate that Hcy serves as an
important atherosclerotic factor. It has been found that Hcy
may induce vascular damage via initiating oxidative stress and
reducing the availability of nitric oxide that is a powerful
vasodilator (Perna et al., 2003). These mechanisms underlie
well-established links between elevated Hcy levels or MTHFR
polymorphisms and cardiovascular diseases including coronary
artery disease, myocardial infarction, cerebrovascular disease
and peripheral occlusive disease (Mangoni and Jackson, 2002;
Trimmer, 2013).
In the recent years, there is a growing interest in the
causative links between Hcy and neuropsychiatric disorders.
High Hcy levels are increasingly recognized as a risk factor
for age-related cognitive deficits together with various types
of dementia (Stanger et al., 2009). Studies in this field have
provided several links between Hcy and domains of cognitive
functioning (Faux et al., 2011; Kim et al., 2013). However,
less attention has been paid to cognitive correlates of ele-
vated Hcy level in psychiatric disorders including schizophre-
nia and affective disorders. In this article, we review the role
of Hcy in the pathophysiology of psychiatric disorders includ-
ing schizophrenia and affective disorders focusing on cognitive
correlates.
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MECHANISMS OF HOMOCYSTEINE ACTION—THE
RELEVANCE TO PSYCHIATRIC DISORDERS
The exact neural and behavioral mechanism of Hcy action is
not known. It seems that the interaction of Hcy with gluta-
matergic transmission is the most relevant mechanism explain-
ing the association between Hcy and schizophrenia or affective
disorders. Both Hcy and its oxidative metabolite—homocysteic
acid—serve as agonists within NMDA receptors (Klancnik et al.,
1992; Zhang and Lipton, 1992; Lipton et al., 1997). Stimulation
of NMDA receptors by Hcy increases calcium influx that exerts
neurotoxic effects (Ho et al., 2002). However, in the presence of
low concentrations of glycine, Hcy acts as a partial antagonist
within the glycine site of NMDA receptors. Thus, in case of low
glycine level Hcy manifests its neuroprotective activity (Lipton
et al., 1997) and only high Hcy concentrations may be toxic. On
the other hand, when glycine levels are high (after head trauma
or stroke), low Hcy levels become toxic (Alam et al., 1998).
This dual action of Hcy within NMDA receptors may explain
why elevated Hcy levels might be implicated in schizophrenia,
in which hypofunction of glutamatergic transmission has been
reported and depression that is characterized by up-regulated
glutamatergic activity.
Also, various studies have suggested that Hcy might regulate
the function of other neuromodulators, such as acetylcholine
(Chen et al., 2011) and dopamine, and serotonin (Gao et al.,
2011). Specifically, Gao et al. (2011) have reported that rats with
hyperhomocysteinemia have lower levels of dopamine and sero-
tonin in the cortex than control rats. Other studies suggest that
Hcy regulates synaptic plasticity in the hippocampus (Christie
et al., 2005; Algaidi et al., 2006). These prior studies suggest that
Hcy has multiple functions in the brain; this can likely explain
its links to various psychiatric disorders, including schizophrenia
and affective disorders.
Animals exposed to Hcy exhibit compromised brain energy
metabolism (Streck et al., 2003), altered long-term potentiation,
disturbances of synaptic plasticity and cognitive impairment in
terms of spatial learning (Algaidi et al., 2006) and memory
deficits (Streck et al., 2004). Heterozygous and homozygous
Mthfr knockout mice are also characterized by neurodevelop-
mental retardation and altered cerebellar morphology (Chen
et al., 2001). Other mechanisms of Hcy toxicity that might be
relevant to the pathophysiology of schizophrenia and affective
disorders include oxidative stress (Koz et al., 2010; Loureiro
et al., 2010; Dietrich-Muszalska et al., 2012), neuronal apopto-
sis (Wang et al., 2012), vascular damage (Brown et al., 2007)
and aberrant DNA methylation (Bromberg et al., 2008, 2009;
Kinoshita et al., 2013; Figure 1). Neural studies have shown
that Hcy acts on various brain regions, including the hippocam-
pus (den Heijer et al., 2003; Matté et al., 2009; Chen et al.,
2011), cortex (den Heijer et al., 2003), and the basal ganglia
(Genedani et al., 2010). Higher Hcy levels lead to atrophy in
the frontal, parietal, and temporal areas (Rajagopalan et al.,
2011).
HOMOCYSTEINE AND COGNITION IN HEALTHY INDIVIDUALS
Homocysteine plays an important role in behavioral and cognitive
processes as shown in studies measuring Hcy levels in healthy
elderly subjects (Prins et al., 2002; Dufouil et al., 2003; Teunissen
et al., 2003; Nurk et al., 2005; Feng et al., 2006; Hooshmand et al.,
2012). For example, van den Kommer et al. (2010) reported that
higher Hcy levels are associated with slow information processing
speed in healthy participants. Further, Nurk et al. (2005) found
FIGURE 1 | Mechanisms of homocysteine action as relevant to
neurological and psychiatric disorders. Homocysteine may interact with
NMDA receptors altering glutamatergic transmission, exert toxic effects on
dopaminergic neurons, initiate neuronal apoptosis, induce oxidative stress,
lead to mitochondrial dysfunction and influence DNA methylation altering
gene expression.
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that impaired episodic memory performance is associated with
increased Hcy levels in healthy individuals. Along the same lines,
Garcia et al. (2004) revealed that impaired performance in the
Stroop test correlates with higher levels of Hcy. Studies on the role
of Hcy in cognitive performance in healthy subjects have shown
that Hcy is specifically involved in episodic memory (Faux et al.,
2011; Narayan et al., 2011), spatial learning (Pirchl et al., 2010),
reversal learning (Christie et al., 2005; Algaidi et al., 2006), and
executive function (Narayan et al., 2011). However, it is debatable
whether Hcy plays a role in working memory processes, as some
studies have found they are not related (Narayan et al., 2011),
while other studies found that lowering Hcy levels enhances
working memory (Macpherson et al., 2012).
Recently published results reveal associations between total
Hcy levels and cognitive functions in healthy subjects. It has
been found that lower overall cognitive performance measured
by Cambridge Cognitive Examination (CAMCOG) are associated
with higher Hcy levels (Budge et al., 2002). This study also
revealed an inverse correlation between hippocampal volume
and Hcy levels (Budge et al., 2002). Other studies have found a
positive correlation between total Hcy levels and ventricle-brain
ratios in the anterior and middle ventricular regions in elderly
participants (Sachdev et al., 2002). It has also been reported
that higher Hcy levels are associated with lower scores in Mini
Mental State Examination (MMSE; Kalmijn et al., 1999). It has
been demonstrated that impaired cognition in elderly participants
correlates with Hcy levels, especially for psychomotor speed and
memory functions (Prins et al., 2002).
Recent data show that higher Hcy levels are associated with
silent brain infarctions and subcortical white matter lesions in
older adults (Vermeer et al., 2002). Higher Hcy levels have been
associated with increased prevalence of silent brain infarction and
decreased brain volume in comparison with subjects having lower
total Hcy (Morris, 2003).
HOMOCYSTEINE IN PSYCHIATRIC DISORDERS
Total Hcy level changes have also been shown to be associated with
many psychiatric disorders, including schizophrenia and affective
disorders. These observations stimulated further studies on the
association between elevated Hcy levels and neuropsychiatric
symptoms and disorders.
Patients having cognitive disorders and depression have been
reported in many studies to have low vitamin B12 and folate
levels. In 1980, an important finding by Shorvon et al. (1980) was
published on the neuropsychiatric manifestations in megaloblas-
tic anemia that occurred due to low folate or vitamin B12 levels.
Their study revealed that up to 56% of patients with affective
disorders have serum folate deficiency (Shorvon et al., 1980).
Below, we describe the relationship between changes in Hcy levels
and schizophrenia, depression, and bipolar disorder.
SCHIZOPHRENIA
In 1975, Freeman et al. (1975) described a case of homocystinuria,
caused by a deficient MTHFR activity, accompanied by psychotic-
like behavior that responded to folate treatment. More recently, a
new hypothesis for the development of schizophrenia has been
proposed—the DNA polymorphism-diet-cofactor-development
(DDCD) hypothesis (Johnson, 1999). This hypothesis states that
mutations of genes related to folate and vitamins B metabolism
potentiated by maternal dietary vitamin deficiencies contribute
to the development of schizophrenia. Total Hcy serum levels in
schizophrenia were first measured by Regland et al. (1995). In this
study, elevated Hcy levels were found in 9 out of 20 schizophrenic
patients (Regland et al., 1995).
Subsequently, elevated total Hcy levels have been widely
described in various subgroups of schizophrenia patients
(Muntjewerff et al., 2006; Nishi et al., 2014) including drug-
naïve first-episode psychosis subjects (Kale et al., 2010; Ayesa-
Arriola et al., 2012; García-Bueno et al., 2013) and chronic
schizophrenia patients (Eren et al., 2010). Total Hcy level has
been found to negatively correlate with folate and vitamin B12
levels in this group of patients (Bouaziz et al., 2010). In addition,
some authors have found that Hcy levels are higher especially
in young male schizophrenia patients (Levine et al., 2002). It
has also been estimated that a 5-µmol increase in plasma Hcy
level may increase the risk of schizophrenia by 70% (Muntjewerff
et al., 2006). Several studies have proved a positive correlation
between Hcy levels and the severity of schizophrenia negative
symptoms (Goff et al., 2004; Petronijevic´ et al., 2008; Bouaziz
et al., 2010; Misiak et al., 2014). These studies are in concordance
with the studies showing a negative correlation between duration
of untreated psychosis (DUP) and Hcy levels (Ayesa-Arriola et al.,
2012; Misiak et al., 2014). The association of increased Hcy
levels with schizophrenia psychopathology has provided grounds
for add-on therapies with vitamin supplementation (Hill et al.,
2011; Roffman et al., 2013). The largest randomized, double-
blind and placebo-controlled study of folic acid and vitamin B12
supplementation revealed the improvement of negative symp-
toms in schizophrenia patients. However, this supplementation
strategy was effective only in patients being homozygotes of the
484T > C polymorphism in the FOLH1 gene that encodes folate
hydrolase involved in intestinal folate transport (Roffman et al.,
2013).
Elevated Hcy levels found in first-episode psychosis patients
suggest that one-carbon metabolism alterations may share com-
mon genetic underpinnings with schizophrenia. Another proof
for this assumption is that siblings of schizophrenia patients are
also characterized by increased plasma Hcy levels (Geller et al.,
2013) and schizophrenia patients with positive family history of
schizophrenia in first or second degree relatives have significantly
higher Hcy levels compared to those with negative family his-
tory of schizophrenia (Misiak et al., 2014). Several studies have
reported an association of two common polymorphisms in the
MTHFR gene (C677T and A1298C) with schizophrenia (Lewis
et al., 2005; Muntjewerff et al., 2006; Gilbody et al., 2007; Shi
et al., 2008). Furthermore, these polymorphisms have been found
to predict the development of metabolic syndrome following the
treatment with antipsychotics or at least might be associated with
increased incidence of metabolic disturbances, such as visceral
obesity, impaired metabolism of glucose and lipids (Misiak et al.,
2013). Furthermore, schizophrenia patients with the comorbid
metabolic syndrome are characterized by higher Hcy levels in
comparison with those, who do not meet the criteria of metabolic
syndrome (Vuksan-C´usa et al., 2011, 2013).
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Although the MTHFR gene polymorphisms are known to
influence the risk of metabolic adverse effects of antipsychotics,
the influence of antipsychotic treatment on Hcy requires fur-
ther investigation due to scarcity of well-designed studies. There
is only one observational study on drug-naïve first episode
schizophrenia patients showing the lack of significant changes
in Hcy levels in the course of antipsychotic pharmacother-
apy (Bicikova et al., 2011). Another study on acutely relapsed
schizophrenia patients has revealed significantly higher Hcy lev-
els during symptomatic exacerbation than during the remission
phase (Petronijevic´ et al., 2008). In turn, the cross-sectional
study by Eren et al. (2010) on chronic schizophrenia patients
revealed significantly lower levels of plasma folate, but not
Hcy or vitamin B12, in patients receiving higher doses of
typical antipsychotics (chlorpromazine equivalent >400 mg).
Another cross-sectional study revealed no significant difference
in Hcy level between schizophrenia patients receiving cloza-
pine in monotherapy and healthy controls (Wysokin´ski and
Kłoszewska, 2013). There is also one study showing a positive
relationship between Hcy levels and N-desmethyl-olanzapine
concentration that is one of the main olanzapine metabo-
lites (Lu et al., 2013). These inconsistent results might be
attributed to heterogenous methodology such as the recruit-
ment of different patients defined by illness duration or symp-
tomatic presentation, as well as the lack of adjustment for
possible confounders including the MTHFR genotype, dietary
habits, cigarette smoking or other known factors influencing Hcy
metabolism.
Several studies have established direct links between the
MTHFR gene polymorphisms and cognitive dysfunction in
terms of executive function and blunted response to errors
in schizophrenia. It has been found that the 677T variant of
the MTHFR gene induces a dose-dependent blunting of dor-
sal anterior cingulate cortex activation in response to errors
using the antisaccade paradigm (Roffman et al., 2011b), posi-
tively correlates with impairments of verbal fluency (Roffman
et al., 2007) and interacts with the 108Val allele in the COMT
gene increasing the number of perseverative errors on the
Wisconsin Card Sorting Task (WCST; Roffman et al., 2008b).
Although the MTHFR gene variants have been reported to influ-
ence certain domains of cognitive functioning in schizophrenia
patients, Hcy levels have not been found to correlate with cog-
nitive impairment in first-episode schizophrenia spectrum dis-
orders patients (Ayesa-Arriola et al., 2012). These discrepancies
suggest that other Hcy-independent consequences of one-carbon
metabolism dysfunction due to genetic factors are implicated
in the occurrence of cognitive impairment in schizophrenia.
Given that the 677T allele in the MTHFR gene is associated
with lower genomic DNA methylation (Friso et al., 2002), it
might be hypothesized that epigenetic phenomena are involved
in cognitive impairment in schizophrenia. Furthermore, the
677T variant enhances dopamine metabolism (Roffman et al.,
2008a,b), which is linked to schizophrenia pathophysiology and
is implicated in the activation of dorsal anterior cingulate cor-
tex in response to errors (Holroyd and Coles, 2002) and influ-
ences prefrontally-mediated executive functioning (Tan et al.,
2007).
DEPRESSION
Several studies have established that depressive episodes may
predict the development of cardiovascular diseases (de Jonge
et al., 2014). These findings suggest that depression is linked to co-
occurring metabolic deregulation increasing cardiovascular risk.
Indeed, elevated Hcy levels have been shown in major depression
(Folstein et al., 2007; Yapislar et al., 2012; Delport et al., 2014; Lok
et al., 2014). Notably, it has been found that Hcy level negatively
correlates with vitamin B12 and folate levels in depressed patients
(Ebesunun et al., 2012). There are also studies showing that the
MTHFR C677T polymorphism may increase the susceptibility
to major depression (Wu et al., 2013; Delport et al., 2014; Lok
et al., 2014; Shen et al., 2014). Interestingly, it has been found that
the MTHFR 677T allele may interact with childhood traumatic
events influencing the time to recurrence in major depressive
disorder (Lok et al., 2013). Indeed, the carriers of the MTHFR
677T allele with childhood traumatic events had shorter time
to recurrence of major depressive disorder in comparison with
those without such events. These findings corroborate emerging
evidence indicating that posttraumatic stress disorder (PTSD)
patients are also characterized by elevated Hcy levels (Levine et al.,
2008; Jendricko et al., 2009).
In the recent study with older adults, it was found that serum
folate levels correlate with the severity of depressive symptoms
(Ebly et al., 1998). In studies that failed to prove an association
between low serum folic acid and depression, there was a negative
correlation between folate level and the duration of the depressive
episode, or a negative correlation between folate level and length
of hospitalization and therefore with treatment outcome. Regard-
ing the severity of depression, patients with lower folate levels
were more severely depressed than those with normal folate levels
(Alpert et al., 2000). In the Womens Health and Aging Study, low
vitamin B12 levels were reported in elderly disabled community
participants and significant vitamin B12 deficiency was more
common among depressed than healthy participants. Significant
vitamin B12 deficiency was associated with a two-fold higher
risk of developing severe depression (Penninx et al., 2000). Inter-
estingly, in the study by Gabryelewicz et al. (2007), depression
and higher baseline Hcy levels were the strongest predictors of
conversion from mild cognitive impairment (MCI) to dementia.
Elevated total Hcy levels were also observed in the study of 213
patients with major depression compared with controls (Fava
et al., 1997). S-Adenosyl Methionine (SAM), a precursor of Hcy,
is used in some countries as an effective adjuvant therapy in the
treatment of depression. On the basis of a meta-analysis, Bressa
(1994) also suggested that SAM can act as an antidepressive agent.
S-Adenosyl Methionine has also been found to be effective in the
treatment of depression related to Parkinsons disease (Di Rocco
et al., 2000). Studies on patients with geriatric depression have
revealed correlations between Hcy and cognitive performance.
In this group of patients, Hcy level positively correlated with
language processing and processing speed (Alexopoulos et al.,
2010).
BIPOLAR DISORDER
Although elevated Hcy levels have been repeatedly reported
in bipolar disorder patients (Baek et al., 2013), no significant
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differences have been found across various mood states (Chiarani
et al., 2013). Studies on bipolar disorder indicate that high
Hcy levels are significantly more frequent among males than
females with bipolar depressive episode (Permoda-Osip et al.,
2013b, 2014b). Similarly to schizophrenia and major depression
patients, an inverse relationship between Hcy and both folate
vitamin B12 levels has been demonstrated in bipolar disorder
subjects (Permoda-Osip et al., 2013b). However, it has been found
that Hcy level negatively correlates with the level of endothelial
damage markers including E-selectin and intracellular adhesion
molecule-1 (ICAM-1) in bipolar depression subjects suggesting
that the pathways of cardiovascular risk are not associated with
Hcy metabolism in this group of patients (Permoda-Osip et al.,
2013b).
As similar to schizophrenia, two common polymorphisms in
the MTHFR gene (C677T and A1298C) might increase the risk
of bipolar disorder and predict the development of comorbid
metabolic syndrome suggesting the existence of common genetic
underpinnings (Peerbooms et al., 2011; Ellingrod et al., 2012).
There is also one study showing an association between the
T833C polymorphism in the CBS gene and bipolar disorder risk
(Permoda-Osip et al., 2014a).
However, in contrast to studies on schizophrenia, evidence
for the influence of Hcy on cognition is more convincing. There
are studies showing an inverse relationship between plasma Hcy
and verbal learning, executive function or immediate memory
in euthymic bipolar disorder patients (Dittmann et al., 2007,
2008; Osher et al., 2008). It should be noted that two studies
consistently reported the correlation between Hcy levels and
executive functioning measured in terms of cognitive flexibil-
ity tapped by Trail Making Test subtest B (Osher et al., 2008)
and perseverative errors assessed on WCST (Dittmann et al.,
2007). Notably, these findings overlap with the influence of
MTHFR polymorphisms on cognitive performance reported in
schizophrenia patients (Roffman et al., 2007, 2008a,b, 2011a,b).
As mentioned above, the C677T polymorphism in the MTHFR
gene has been associated with greater deficits of executive func-
tioning assessed on WCST in schizophrenia subjects (Roffman
et al., 2007).
Cognitive deficits due to elevated Hcy level might be par-
ticularly prominent among older bipolar disorder patients or
those with a delayed onset of the disorder (Dias et al., 2009).
However, it should be kept in mind that aging increases Hcy
levels and some cognitive deficits due to hyperhomocysteinemia
may occur regardless of depression. It has been shown that
hyperhomocysteinemia worsens cognitive performance in tests
of immediate or delayed memory, as well as global cognitive
functioning in older subjects (Ford et al., 2013). It should also
be noted that patients with bipolar disorder might exhibit higher
Hcy levels due to the treatment with mood stabilizers. Indeed,
experimental studies have revealed that sodium valproate inhibits
methionine adenosyltransferase, while lamotrigine serves as a
weak dihydrofolate reductase inhibitor leading to lower functional
folate levels despite of normal blood levels of folate (Baek et al.,
2013).
There are two randomized placebo controlled trials
investigating the efficacy of folic acid supplementation in
bipolar depression. These studies revealed that folic acid
may enhance lithium prophylaxis (Coppen et al., 1986)
and antidepressant action of fluoxetine in females (Coppen
and Bailey, 2000). Furthermore, it has been found that the
augmentation of sodium valproate with folic acid might be
beneficial in terms of reducing manic symptoms (Behzadi
et al., 2009). Inconsistent results also indicate that higher
vitamin B12 level may predict favorable response to single
ketamine infusion in bipolar depression patients (Permoda-
Osip et al., 2013a; Lundin et al., 2014). Ketamine is an
NMDA receptor antagonist, emerging as a therapeutic
strategy in treatment-resistant depression (Naughton et al.,
2014).
FUTURE DIRECTIONS AND CONCLUSION
Undoubtedly, elevated Hcy levels are associated with a wide spec-
trum of psychiatric disorders including particularly schizophrenia
and affective disorders. It might be assumed that the dual action
of Hcy (as agonist or antagonist) within NMDA receptors (Lipton
et al., 1997) explains why elevated Hcy levels are involved in the
pathophysiology of both schizophrenia and affective disorders.
This association is probably strengthened by high prevalence
of metabolic syndrome and its single components, which is
a consequence of antipsychotic treatment. Emerging evidence
indicates that high Hcy levels may, to some extent, account for
cognitive deficits among these groups of patients. It seems that
the influence of Hcy on executive functioning occurs regard-
less of a psychiatric diagnosis since this correlation has been
found both in schizophrenia and bipolar disorder patients. In
this regard, it is also recommended to investigate the influence
of Hcy on cognition in healthy adults in order to determine
the extent of cognitive deficits that are the consequence of ele-
vated Hcy levels. Further, future studies should investigate the
relationship between Hcy levels in these patient populations on
and off their medications to tease apart the relationship between
Hcy, psychiatric disorders, and treatment duration or type of
medications.
There is still a scarcity of studies investigating the relationship
between Hcy and cognitive deficits in drug-naïve first-episode
patients and high-risk populations. These studies are warranted
as they may indicate the correlation between Hcy levels and early
cognitive deficits that are strictly associated with schizophrenia
and affective disorders regardless of medication and disease dura-
tion. Irrespective of a diagnostic subgroup, future studies should
take into account the confounding effect of such variables as body
weight, dietary habits, smoking or alcohol consumption that are
less frequently controlled, as previous studies have shown that
these variables are correlated with Hcy levels and may thus con-
found findings in the relationship between psychiatric disorders
and Hcy levels. Given the largely known contribution of Hcy
to the etiology of various types of dementia, it might be also
beneficial to address the role of Hcy in the neuroprogression of
cognitive deficits that is widely observed particularly in affective
disorders and remains the matter of dispute in schizophrenia.
Longitudinal measurements of Hcy along with assessment of
cognitive functioning that take into account the effects of age as
an confounding factor are required to initiate this vein of research.
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It should be noted that supplementation of folic acid and
vitamins B may normalize Hcy levels. However, we are not
aware of any studies addressing the efficacy of supplementation
strategies with respect to alleviating cognitive deficits among
patients with schizophrenia or affective disorders. Similarly, a gap
exists in addressing the influence of antipsychotic treatment on
Hcy metabolism, and its correlations with cognitive processes,
which should be the focus in future work. As mentioned above,
there is only one cross-sectional study revealing a negative cor-
relation between folate levels and high chlorpromazine equiva-
lents (>400 mg/day) (Eren et al., 2010) in chronic schizophrenia
patients and one observational study performed in a small sample
of drug-naïve first-episode schizophrenia patients reporting no
significant alterations in Hcy levels in the course of antipsy-
chotic treatment (Bicikova et al., 2011). Another study revealed
a decrease in Hcy levels during the treatment of acute relapse of
schizophrenia (Petronijevic´ et al., 2008). This issue is important
due to the known influence of certain antipsychotics on the
development of obesity and its metabolic consequences, such as
dyslipidemia, diabetes or hypertension that have been found to
influence cognitive performance in schizophrenia patients (Lan-
con et al., 2012; Lindenmayer et al., 2012; Boyer et al., 2013; Li
et al., 2014).
Results of studies based on candidate gene approach and inves-
tigating genetic variation within the Hcy metabolism enzymes
should be interpreted with caution. Previous genome-wide asso-
ciation studies (GWAS) have not confirmed the association
between polymorphisms in the MTHFR gene or other genes
implicated in Hcy metabolism and schizophrenia (Yoshimi et al.,
2010; Lencz et al., 2013; Ripke et al., 2013, 2014; Ivorra et al.,
2014; Saito et al., 2014) or bipolar disorder (Sklar et al., 2011;
Kuo et al., 2014; Mühleisen et al., 2014; Xu et al., 2014) risk.
There is only one genome-wide linkage analysis of recurrent
depressive disorder providing evidence for linkage on chromo-
some region 1p36 including the MTHFR gene with the LOD
score for female-female pairs estimated at 2.73 (McGuffin et al.,
2005). In this regard and taking into account the involve-
ment of Hcy pathway in several physical health impairments,
it might be hypothesized that discordant results of GWAS and
candidate gene approach studies may originate from genetic
heterogeneity across studied populations and various clini-
cal phenotypes including distinct somatic comorbidities that
have also been attributed to polymorphisms in the MTHFR
gene.
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